Création et validation d’une classification en grade de sévérité dans les maladies neuromusculaires : la classification NM-Score
Vuillerot C, Rippert P, Roche S, Bérard C, Margirier F, de Lattre C, Poirot I, Berruyer A, Tiffreau V, Fournier-Mehouas M, Bouhour F, Urtizberea JA, Renders A, Ecochard R; Le groupe d’étude NM-Score.
Ann Phys Rehabil Med. 2013. 56(9-10):673-86.
Development of a classification for neuromuscular disease patients in each of the three motor function domains (D1: standing and transfers; D2: axial and proximal function; D3: distal function). Several qualitative validation studies (according to the Delphi method) and quantitative validation studies (content validity, criterion validity and inter-rater reliability) were used. The inter-rater agreement was good when the classification was based on patient observation or an interview with the patient. Stronger correlations (according to Spearman’s coefficient) with the respective ‘‘gold standard’’ classifications were found for NM-Score D1 (0.86 vs. the Vignos Scale and [1]0.88 vs. MFM]-D1 and NM-Score D2 ([1]0.7 vs. the Brooke Scale and 0.64 vs. MFM-D2) than for NM-Score D3 (0.49 vs. the Brooke scale and [1]0.49 vs. MFM-D3). The NM-Score is a reliable, reproducible outcome measure with value in clinical practice and in clinical research for the description of patients and the constitution of uniform patient groups (in terms of motor function).
Keywords: Activities of daily living, Motor function, Neuromuscular disease, Outcome measure
Articles dans les revues scientifiques
Short-TERM Neuromuscular Electrical Stimulation Training of the Tibialis Anterior Did Not Improve Strength and Motor Function in Facioscapulohumeral Muscular Dystrophy Patients
Doix AM, Roeleveld K, Garcia J, Lahaut P, Tanant V, Fournier-Mehouas M, Desnuelle C, Colson SS, Sacconi S Am J Phys Med Rehabil. 2017. 96(4):e56-e63. Prospective study including 10 patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1) and 10 healthy...
Upper extremity outcome measures for collagen VI-related myopathy and LAMA2-related muscular dystrophy
Bendixen RM, Butrum J, Jain MS, Parks R, Hodsdon B, Nichols C, Hsia M, Nelson L, Keller KC, McGuire M, Elliott JS, Linton MM, Arveson IC, Tounkara F, Vasavada R, Harnett E, Punjabi M, Donkervoort S, Dastgir J, Leach ME, Rutkowski A, Waite M, Collins J, Bönnemann CG,...
Reliability of home-based, motor function measure in hereditary neuromuscular diseases
Ruiz-Cortes X, Ortiz-Corredor F, Mendoza-Pulido C J Int Med Res. 2017. 45(1):261-271. The goal of the study was to compare the reliability of the MFM scale in the assessment of patients when administered at home and clinic. Results demonstrated excellent inter-rater...
Longitudinal Functional and NMR Assessment of Upper Limbs in Duchenne Muscular Dystrophy
Hogrel JY, Wary C, Moraux A, Azzabou N, Decostre V, Ollivier G, Canal A, Lilien C, Ledoux I, Annoussamy M, Reguiba N, Gidaro T, Le Moing AG, Cardas R, Voit T, Carlier PG, Servais L. Neurology. 2016. 15;86(11):1022-30. Twenty-five 53-skippable patients with DMD were...
Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial
Schmidt S, Gocheva V, Zumbrunn T, Rubino-Nacht D, Bonati U, Fischer D, Hafner P Trials. 2017. 9;18(1):116. Protocol of a randomized, double-blind, placebo-controlled trial aiming to demonstrate determine if treatment with L-citrulline shows a positive effect on...
Postrehabilitation Functional Improvements in Patients With Inflammatory Myopathies: The Results of a Randomized Controlled Trial
Tiffreau V, Rannou F, Kopciuch F, Hachulla E, Mouthon L, Thoumie P, Sibilia J, Drumez E, Thevenon A Arch Phys Med Rehabil. 2017. 98(2):227-234. Multicenter randomized controlled trial, aiming to evaluate the medium-term functional effect and the effect on quality of...